Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07267000 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

EXERCISE AND THE IMMUNE RESPONSE IN LUNG CANCER

Study acronym: ImmuEX
StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

  1. Site contact updatedv3
  2. Trial status: Not Yet Recruiting to Recruiting Enrollment target: 100 to 50 · Start date changed from estimate of Jan 1, 2026 to Apr 1, 2026 · Primary endpoint revised · 6 morev2 Show 9 more changesShow less
    • Enrollment target: 100 to 50
    • Start date changed from estimate of Jan 1, 2026 to Apr 1, 2026
    • Primary endpoint revised
    • Eligibility criteria expanded, about 6 words
    • Secondary endpoints: 4 to 7
    • Study description expanded, about 43 words
    • Site details revised
    • Collaborators: 2 to 1
    • Study title shortened, about 6 words

    See this version in full on ClinicalTrials.gov ↗

  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This project is about the effect of a 12-week training therapy intervention in patients suffering from non-small cell and small-cell lung cancer. It has widely been accepted that exercise is preventive against certain types of cancer. Individuals following an active lifestyle have a significantly lower risk for several chronic diseases, including cancer, as compared to sedentary ones. However, evidence is still lacking for exercise as part of routine cancer treatment. It has widely been accepted that exercise strongly impacts immune response, and might influence antitumor immune response as well. In this study, patients suffering from lung cancer undergo either a 12-week training program consisting of moderate-intensity continuous exercise (MICE), or a 12-week program with high-intensity interval exercise. Both groups will be compared to a control group receiving standard exercise recommendations. The immunologic response, i.e. cytokine profiles and changes in peripheral blood mononuclear cell (PBMC) characteristics will be the main endpoint. Blood will be taken from the patients at different timepoints, and blood samples will be tested for these immunologic changes. FACS analysis will be used to assess the properties of immune cells and potential changes upon the exercise regimen. Mitochondrial function will be assessed via the Seahorse machine, and mass spectrometry (lipidomics) will be used for the analysis of lipid profile changes.
Trial Details
NCT Number NCT07267000
Lead Sponsor Medical University of Graz
Collaborators: Austrian Science Fund (FWF)
Conditions Non-Small Cell Lung Cancer, Exercise Training, Immunotherapy, Small Cell Cancer Of The Lung
Enrollment 50 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov